Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Journal of Pharmacy Practice
|
December 27, 2017
An Interdisciplinary Academic Detailing Approach to Decrease Inappropriate Medication Prescribing by Physician Residents for Older Veterans Treated in the Emergency Department
Jason M Moss, William E Bryan, Loren M Wilkerson, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
The Discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma
Takeru Ehara, Christopher M Adams, Doug Bevan, et al.
Journal of Medicinal Chemistry
|
November 17, 2015
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
Erik L Meredith, Nello Mainolfi, Stephen Poor, et al.
Journal of Medicinal Chemistry
|
April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
Rajeshri G Karki, James Powers, Nello Mainolfi, et al.
Journal of Neurointerventional Surgery
|
July 25, 2014
Platelet function inhibitors and platelet function testing in neurointerventional procedures
Chirag D Gandhi, Ketan R Bulsara, Johanna Fifi, et al.
Journal of Medicinal Chemistry
|
February 6, 2018
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
Christopher M Adams, Karen Anderson, Gerald Artman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 17, 2004
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice
Mark Veugelers, David Wilkes, Kimberly Burton, et al.
Biorxiv : the Preprint Server for Biology
|
September 2, 2025
Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas
Xiaojing Wang, Maite Calucho, Cynthia M Estrada-Zuniga, et al.
The Cochrane Database of Systematic Reviews
|
May 1, 2015
Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people
Lee Hooper, Asmaa Abdelhamid, Natalie J Attreed, et al.
Journal of Medicinal Chemistry
|
February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
Nello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Journal of Pharmacy Practice
|
December 27, 2017
An Interdisciplinary Academic Detailing Approach to Decrease Inappropriate Medication Prescribing by Physician Residents for Older Veterans Treated in the Emergency Department
Jason M Moss, William E Bryan, Loren M Wilkerson, et al.
Journal of Medicinal Chemistry
|
March 3, 2018
The Discovery of ( S)-1-(6-(3-((4-(1-(Cyclopropanecarbonyl)piperidin-4-yl)-2-methylphenyl)amino)-2,3-dihydro-1 H-inden-4-yl)pyridin-2-yl)-5-methyl-1 H-pyrazole-4-carboxylic Acid, a Soluble Guanylate Cyclase Activator Specifically Designed for Topical Ocular Delivery as a Therapy for Glaucoma
Takeru Ehara, Christopher M Adams, Doug Bevan, et al.
Journal of Medicinal Chemistry
|
November 17, 2015
Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration
Erik L Meredith, Nello Mainolfi, Stephen Poor, et al.
Journal of Medicinal Chemistry
|
April 18, 2019
Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway
Rajeshri G Karki, James Powers, Nello Mainolfi, et al.
Journal of Neurointerventional Surgery
|
July 25, 2014
Platelet function inhibitors and platelet function testing in neurointerventional procedures
Chirag D Gandhi, Ketan R Bulsara, Johanna Fifi, et al.
Journal of Medicinal Chemistry
|
February 6, 2018
The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration
Christopher M Adams, Karen Anderson, Gerald Artman, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 17, 2004
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice
Mark Veugelers, David Wilkes, Kimberly Burton, et al.
Biorxiv : the Preprint Server for Biology
|
September 2, 2025
Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas
Xiaojing Wang, Maite Calucho, Cynthia M Estrada-Zuniga, et al.
The Cochrane Database of Systematic Reviews
|
May 1, 2015
Clinical symptoms, signs and tests for identification of impending and current water-loss dehydration in older people
Lee Hooper, Asmaa Abdelhamid, Natalie J Attreed, et al.
Journal of Medicinal Chemistry
|
February 20, 2020
Discovery of 4-((2<i>S</i>,4<i>S</i>)-4-Ethoxy-1-((5-methoxy-7-methyl-1<i>H</i>-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases
Nello Mainolfi, Takeru Ehara, Rajeshri G Karki, et al.
Page
of 5